Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes.
Animals
Berberine
/ pharmacology
Cytokines
/ metabolism
Endoplasmic Reticulum Stress
/ drug effects
Hepatocytes
/ drug effects
Inflammation
/ chemically induced
Lipopolysaccharides
/ toxicity
Macrophages
/ drug effects
Male
Mice
Mice, Inbred C57BL
Non-alcoholic Fatty Liver Disease
/ chemically induced
Palmitic Acid
/ toxicity
RAW 264.7 Cells
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
03
2020
accepted:
17
04
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
6
8
2020
Statut:
epublish
Résumé
Inflammation plays an essential role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Berberine (BBR), an isoquinoline alkaloid isolated from Chinese medicinal herbs, has been widely used to treat various diseases, including liver diseases for hundreds of years. The previous studies have shown that BBR inhibits high fat-diet-induced steatosis and inflammation in rodent models of NAFLD. However, the underlying molecular mechanisms remain unclear. This study is aimed to identify the potential mechanisms by which BBR inhibits free fatty acid (FFA) and LPS-induced inflammatory response in mouse macrophages and hepatocytes. Mouse RAW264.7 macrophages and primary mouse hepatocytes were treated with palmitic acid (PA) or LPS or both with or without BBR (0-10 μM) for different periods (0-24 h). The mRNA and protein levels of proinflammatory cytokines (TNF-α, IL-6, IL-1β, MCP-1) and ER stress genes (CHOP, ATF4, XBP-1) were detected by real-time RT-PCR, Western blot and ELISA, respectively. The results indicated that BBR significantly inhibited PA and LPS-induced activation of ER stress and expression of proinflammatory cytokines in macrophages and hepatocytes. PA/LPS-mediated activation of ERK1/2 was inhibited by BBR in a dose-dependent manner. In summary, BBR inhibits PA/LPS-induced inflammatory responses through modulating ER stress-mediated ERK1/2 activation in macrophages and hepatocytes.
Identifiants
pubmed: 32357187
doi: 10.1371/journal.pone.0232630
pii: PONE-D-20-07442
pmc: PMC7194368
doi:
Substances chimiques
Cytokines
0
Lipopolysaccharides
0
Berberine
0I8Y3P32UF
Palmitic Acid
2V16EO95H1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0232630Subventions
Organisme : BLRD VA
ID : I01 BX001390
Pays : United States
Organisme : NIAAA NIH HHS
ID : F30 AA026470
Pays : United States
Organisme : BLRD VA
ID : IS1 BX004777
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK115377
Pays : United States
Organisme : BLRD VA
ID : I01 BX004033
Pays : United States
Organisme : NIAAA NIH HHS
ID : R21 AA026629
Pays : United States
Organisme : BLRD VA
ID : IK6 BX004477
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK104893
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK057543
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Biochem Pharmacol. 2009 Jul 1;78(1):70-7
pubmed: 19447225
Am J Physiol Endocrinol Metab. 2013 Oct 1;305(7):E853-67
pubmed: 23921144
Free Radic Biol Med. 2019 Sep;141:192-204
pubmed: 31226399
BMC Complement Altern Med. 2017 Feb 20;17(1):120
pubmed: 28219355
Nutr J. 2016 Aug 02;15(1):72
pubmed: 27485440
Am J Physiol Endocrinol Metab. 2018 Nov 1;315(5):E745-E757
pubmed: 29989851
PLoS One. 2010 Feb 09;5(2):e9069
pubmed: 20161729
Mol Pharmacol. 2005 Sep;68(3):690-700
pubmed: 15976036
World J Cardiol. 2010 Apr 26;2(4):71-7
pubmed: 21160701
Hepatology. 1988 Mar-Apr;8(2):358-65
pubmed: 3356417
Front Genet. 2014 May 09;5:112
pubmed: 24847353
Cell Death Dis. 2019 Jun 13;10(6):468
pubmed: 31197160
J Transl Med. 2016 Sep 15;14:266
pubmed: 27629750
Int J Med Sci. 2019 Oct 21;16(12):1593-1603
pubmed: 31839747
Nature. 2008 Jul 24;454(7203):455-62
pubmed: 18650916
Gastroenterology. 2010 Jan;138(1):197-209
pubmed: 19732776
Nutr Rev. 2015 Jun;73(6):376-85
pubmed: 26011912
Cell. 2010 Mar 19;140(6):900-17
pubmed: 20303879
Dig Dis Sci. 2016 May;61(5):1294-303
pubmed: 26841783
Osteoarthritis Cartilage. 2016 May;24(5):942-5
pubmed: 26687823
Nutrients. 2013 May 10;5(5):1544-60
pubmed: 23666091
Hepatology. 2017 Jun;65(6):2005-2018
pubmed: 28120434
Int J Mol Sci. 2014 Apr 11;15(4):6184-223
pubmed: 24733068
Gastroenterology. 2018 Aug;155(2):282-302.e8
pubmed: 29906416
Dig Liver Dis. 2019 Aug;51(8):1154-1163
pubmed: 31003959
Hepatology. 2013 Mar;57(3):1005-16
pubmed: 23080229
Molecules. 2016 Oct 14;21(10):
pubmed: 27754444
FASEB J. 2019 Jun;33(6):7289-7300
pubmed: 30848932
Eur J Pharmacol. 2004 Oct 1;500(1-3):221-30
pubmed: 15464035
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
Apoptosis. 2009 Aug;14(8):996-1007
pubmed: 19360473
Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2395-402
pubmed: 22427564
Exp Ther Med. 2019 Mar;17(3):2091-2098
pubmed: 30867696
Lipids Health Dis. 2019 Mar 25;18(1):71
pubmed: 30909920
Evid Based Complement Alternat Med. 2014;2014:289264
pubmed: 24669227
PLoS One. 2015 Aug 07;10(8):e0134172
pubmed: 26252777
PLoS One. 2013;8(1):e54349
pubmed: 23372711
Nat Rev Drug Discov. 2008 Dec;7(12):1013-30
pubmed: 19043451
Sci Rep. 2013;3:1142
pubmed: 23359618
Am J Physiol Gastrointest Liver Physiol. 2006 Dec;291(6):G1071-80
pubmed: 16861219
Atherosclerosis. 2007 Nov;195(1):e134-43
pubmed: 17531241
World J Gastroenterol. 2012 Feb 28;18(8):727-35
pubmed: 22371632
Nutrients. 2017 Oct 16;9(10):
pubmed: 29035308
Sci Rep. 2016 Feb 09;6:20848
pubmed: 26857750
World J Hepatol. 2017 Jun 8;9(16):715-732
pubmed: 28652891
Front Pharmacol. 2020 Jan 08;10:1504
pubmed: 31969822
Int J Mol Sci. 2017 Dec 29;19(1):
pubmed: 29286292
Curr Med Sci. 2019 Feb;39(1):37-43
pubmed: 30868489
Cells. 2020 Jan 11;9(1):
pubmed: 31940841
Biomed Pharmacother. 2017 Nov;95:1777-1788
pubmed: 28962083